Athenex Stock News

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX ) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing. Proceeds from the sale will be used to service the Company''s debt obligations and for other general corporate purposes. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. Upon the closing, ImmunityBio will assume all capital expenditure and hiring obligations of Athenex pursuant to its agreements with New York State. Athenex will continue to operate its existing Athenex Pharmaceutical Division (APD) and Athenex Pharmaceutical Solutions (APS) divisions.

Athenex Inc (ATNX) shares closed today at 1.6% above its 52 week low of $1.25, giving the company a market cap of $138M. The stock is currently down 6.6% year-to-date, down 89.1% over the past 12 months, and down 89.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 30.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -511.2% The company's stock price performance over the past 12 months lags the peer average by 14007.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

公司將於今天上午 9:00（美國東部時間）舉辦一場虛擬關鍵意見領袖活動， 討論其「CAR-NKT 嵌合抗原受體自然殺手T細胞 」治療平台

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform

Athenex Inc. (NASDAQ:ATNX) has a beta value of 0.56 and has seen 2.34 million shares traded in the last trading session. The company, currently valued at $189.43M, closed the last trade at $1.77 per share which meant it lost -$0.01 on the day or -0.56% during that session. The ATNX stock price is -747.46% off Athenex Inc. (ATNX) Has Fallen -0.56%, Becoming A Losing Stock For Investors Read More »

Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting

(RTTNews) - Athenex, Inc. (ATNX) said its Marketing Authorization Application for oral Paclitaxel for the treatment of advanced breast cancer has been validated by the United Kingdom''s Medicines and Healthcare products Regulatory Agency for review. A single pivotal phase III study of oral Paclitaxel was the basis of the Marketing Authorization

BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdoms (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for review . The application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.

California State Teachers Retirement System raised its position in shares of Athenex, Inc. (NASDAQ:ATNX) by 11.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,153 shares of the companys stock after acquiring an additional 12,279 shares during the quarter. California State []

Charles Schwab Investment Management Inc. raised its position in Athenex, Inc. (NASDAQ:ATNX) by 14.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 531,906 shares of the companys stock after acquiring an additional 67,618 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Athenex were worth $2,458,000 at the end of the []

Athenex Inc''s (NASDAQ: ATNX ) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium. The abstract and poster provide data from a post hoc, subgroup … Full story available on Benzinga.com

安全性數據分析表明，肝功能檢查升高的患者發生中性粒細胞減少相關毒性的風險增加